Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

NCT07292298 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT07292298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07292298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Recruiting
Start date
November 30, 2026
Completion date
November 30, 2031
Enrollment
44 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rectal adenocarcinoma, rectal cancer